Replies to post #736864 on NorthWest Biotherapeutics Inc (NWBO)

[CherryTree1]

HaaaaHaaaa . . . Not able to refute the post directly are you ick-light . . . so instead you try to deflect.
If you believe my post was manufactured by ChatGTP I challenge you to engage ChatGTP and recreate it.
I'll wait
Actually I tried it with Google's search AI and it comes back with a pretty good answer to my surprise.
I asked it --> why was the primary endpoint for nwbo dcvax-l phase 3 changed

The primary endpoint for the NWBO DCVax-L Phase 3 trial was changed from progression-free survival (PFS) to overall survival (OS) because the initial design could not reliably establish the impact of the vaccine on PFS due to the crossover nature of the trial, where patients in the placebo group eventually received DCVax-L upon tumor recurrence, effectively eliminating a true control group for PFS analysis; therefore, researchers opted to compare the survival data of DCVax-L treated patients to an external control group receiving standard of care to assess overall survival as the primary endpoint.